Preliminary qualification of a machine learning-based assessment of the tumor immune infiltrate as a predictor of outcome in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
Scheiner B, Lombardi P, D'Alessio A, Kim G, Tafavvoghi M, Petrenko O, Goldin RD, Fulgenzi CAM, Torkpour A, Balcar L, Mauri FA, Pomej K, Himmelsbach V, Barsch M, Celsa C, Cabibbo G, Cheon J, Krall A, Hucke F, Di Tommaso L, Bernasconi M, Rimassa L, Samson A, Stefanini B, Mozayani B, Trauner M, Lackner C, Stauber R, Vasuri F, Piscaglia F, Bengsch B, Finkelmeier F, Peck-Radosavljevic M, Rasmussen Busund LT, Marafioti T, Rahbari M, Heikenwalder M, Pinter M, Chon HJ, Rakaee M, Pinato DJ.
Scheiner B, et al. Among authors: vasuri f.
J Immunother Cancer. 2025 Oct 5;13(10):e010975. doi: 10.1136/jitc-2024-010975.
J Immunother Cancer. 2025.
PMID: 41052886
Free PMC article.